TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15734089

Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian drilling (LOD)
Number of subjects: 45
Study: 12017404

Group type: EXPERIMENTAL
Intervention: Formoterol 48 microg via Turbuhaler
Number of subjects: 16

Group type: COMPARATOR
Intervention: Salbutamol 800 microg via pMDI
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Salbutamol 800 microg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Formoterol 48 microg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Formoterol and Salbutamol
Number of subjects: 16
Study: 10607970

Group type: EXPERIMENTAL
Intervention: Psychiatric morbidity (including 'subcases', 'organic' dementia, global depression, 'psychotic' depression, 'neurotic' depression, 'neuroses')
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Non-cases (reference group)
Number of subjects: 1080
Study: 7574568

Group type: COMPARATOR
Intervention: Snack (not-hungry group)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Food-deprived (hungry group)
Number of subjects: 157
Study: 2405556

Group type: EXPERIMENTAL
Intervention: Nifedipine (20-40 mg twice daily)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Captopril (25-50 mg twice daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 19

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 19
Study: 6112526

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg three times a day for 2 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Metoclopramide 15 mg three times a day for 2 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Metoclopramide (any dose)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Metoclopramide (5 mg)
Number of subjects: 37
Study: 30642370

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no stimulation for 12 weeks)
Number of subjects: 0
Study: 28819181

Group type: EXPERIMENTAL
Intervention: Starting bronchoscopy when hypoventilation was detected (Study group)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Starting bronchoscopy when OAAS < 4 (Control group)
Number of subjects: 114
Study: 26096521

Group type: EXPERIMENTAL
Intervention: Yellow Polylens Y30
Number of subjects: 32

Group type: COMPARATOR
Intervention: Orange Series model PC 440Y
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Subjective visual impression
Number of subjects: 32
Study: 24281271

Group type: EXPERIMENTAL
Intervention: Pain assessment in dementia patients
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Pain assessment in dementia patients with severe cognitive impairment
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Pain assessment in dementia patients with low to moderate cognitive impairment
Number of subjects: 272
Study: 21681227

Group type: EXPERIMENTAL
Intervention: Implantable gastric stimulator (IGS) activated
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (IGS inactive)
Number of subjects: 13
Study: 19073791

Group type: EXPERIMENTAL
Intervention: Iron supplementation (7 mg/d as multivitamin preparation with ferrous sulfate)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (multivitamin preparation without iron)
Number of subjects: 75
Study: 17697302

Group type: EXPERIMENTAL
Intervention: Small-incision cholecystectomy (SIC)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Conventional open technique (conversion from SIC or LC)
Number of subjects: 257
Study: 15729570

Group type: EXPERIMENTAL
Intervention: Autoantibody-positive patients
Number of subjects: 4545

Group type: COMPARATOR
Intervention: Autoantibody-negative patients
Number of subjects: 4545
Study: 12414860

Group type: EXPERIMENTAL
Intervention: 7.5 IU (2.5 mg) GH
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 9472909

Group type: EXPERIMENTAL
Intervention: Black hypertensives with Stage 1-2 hypertension
Number of subjects: 0

Group type: COMPARATOR
Intervention: White hypertensives with Stage 1-2 hypertension
Number of subjects: 0
Study: 7629641

Group type: EXPERIMENTAL
Intervention: i.v. tubing directly connected to the infusion device
Number of subjects: 0

Group type: COMPARATOR
Intervention: i.v. tubing connected to the latex port of an i.v. lock using a needle
Number of subjects: 0
Study: 2520899

Group type: EXPERIMENTAL
Intervention: Antiplaque C
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 851246

Group type: EXPERIMENTAL
Intervention: 2‐chloroprocaine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: bupivacaine
Number of subjects: 200
Study: 30695650

Group type: EXPERIMENTAL
Intervention: Ado-Trastuzumab Emtansine
Number of subjects: 0
Study: 30365590

Group type: EXPERIMENTAL
Intervention: 40% (w/w) hydrogen peroxide topical solution (HP40)
Number of subjects: 937

Group type: COMPARATOR
Intervention: Vehicle (VEH)
Number of subjects: 937
Study: 27852282

Group type: EXPERIMENTAL
Intervention: Traditional acupuncture that achieves the De‐qi sensation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham acupuncture without needle insertion
Number of subjects: 60
Study: 25307295

Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl (20 mg once daily)
Number of subjects: 2185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2185
Study: 22233728

Group type: EXPERIMENTAL
Intervention: Woman‐Focused intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nutrition control
Number of subjects: 100
Study: 19384841

Group type: EXPERIMENTAL
Intervention: Blood volume-controlled ultrafiltration (BV-controlled UF)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard haemodialysis (HD)
Number of subjects: 26
Study: 17125466

Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aspirin (500 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aspirin (500 mg) + L-NMMA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aspirin (500 mg) + L-NMMA + Fluconazole (0.37 mg.min(‐1).l(‐1))
Number of subjects: 12
Study: 15766297

Group type: EXPERIMENTAL
Intervention: Haloperidol or penfluridol
Number of subjects: 215
Study: 11865378

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted sigmoidectomy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 42
Study: 10193727

Group type: EXPERIMENTAL
Intervention: Diabetics with proteinuria
Number of subjects: 2784

Group type: EXPERIMENTAL
Intervention: Diabetics without proteinuria
Number of subjects: 2784

Group type: COMPARATOR
Intervention: Nondiabetics
Number of subjects: 2784

Group type: EXPERIMENTAL
Intervention: Diabetics with low concentration proteinuria
Number of subjects: 2784

Group type: EXPERIMENTAL
Intervention: Diabetics with high concentration proteinuria
Number of subjects: 2784
Study: 7851007

Group type: EXPERIMENTAL
Intervention: Malaria peptide-diphtheria toxoid conjugates with aluminium hydroxide as an adjuvant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 2162272

Group type: EXPERIMENTAL
Intervention: Acute hypoglycaemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-selective alpha-adrenergic blockade with phentolamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beta-adrenergic blockade with propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cholinergic blockade with atropine
Number of subjects: 0
Study: 7462697

Group type: EXPERIMENTAL
Intervention: Cold-recombinant influenza A virus (CR 22)
Number of subjects: 0
Study: 29423956

Group type: EXPERIMENTAL
Intervention: Sarolaner
Number of subjects: 81

Group type: COMPARATOR
Intervention: Moxidectin/imidacloprid
Number of subjects: 81
Study: 28027367

Group type: EXPERIMENTAL
Intervention: Penalty hospitals for AMI
Number of subjects: 20351161

Group type: EXPERIMENTAL
Intervention: Penalty hospitals for HF
Number of subjects: 20351161

Group type: EXPERIMENTAL
Intervention: Penalty hospitals for pneumonia
Number of subjects: 20351161

Group type: EXPERIMENTAL
Intervention: Penalty hospitals for nontarget conditions
Number of subjects: 20351161

Group type: EXPERIMENTAL
Intervention: Penalty hospitals for AMI vs nontarget conditions
Number of subjects: 20351161

Group type: EXPERIMENTAL
Intervention: Penalty hospitals for HF vs nontarget conditions
Number of subjects: 20351161

Group type: EXPERIMENTAL
Intervention: Penalty hospitals for pneumonia vs nontarget conditions
Number of subjects: 20351161

Group type: COMPARATOR
Intervention: Nonpenalty hospitals for AMI vs nontarget conditions
Number of subjects: 20351161

Group type: COMPARATOR
Intervention: Nonpenalty hospitals for HF vs nontarget conditions
Number of subjects: 20351161

Group type: COMPARATOR
Intervention: Nonpenalty hospitals for pneumonia vs nontarget conditions
Number of subjects: 20351161
Study: 23660571

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) 300 mg·kg‐1 body mass
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Lactate (LACTATE) 1115 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sodium chloride (PL-BICARB) as placebo for NaHCO3
Number of subjects: 7

Group type: COMPARATOR
Intervention: Plain flour (PL-LACTATE) as placebo for lactate
Number of subjects: 7
Study: 22260629

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Depression Relapse Active Monitoring (DRAM)
Number of subjects: 204
Study: 20056803

Group type: EXPERIMENTAL
Intervention: Sergliflozin etabonate (5-500 mg)
Number of subjects: 30
Study: 17188514

Group type: EXPERIMENTAL
Intervention: Prime-induced activation manipulation in Experiment 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prime-induced activation manipulation in Experiment 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prime-induced activation manipulation in Experiment 3
Number of subjects: 0
Study: 15934109

Group type: EXPERIMENTAL
Intervention: Managed care settings (HMOs)
Number of subjects: 529
Study: 12570928

Group type: EXPERIMENTAL
Intervention: 2 mg 17-beta estradiol (ERT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 2 mg 17-beta estradiol combined with continuous 5 mg medroxyprogesterone acetate (HRT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 10563646

Group type: EXPERIMENTAL
Intervention: Robot training (MIT‐Manus) added to standard rehabilitation treatments
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Robot training (MIT‐Manus)
Number of subjects: 20
Study: 8754408

Group type: EXPERIMENTAL
Intervention: Platelets from patients with chronic glomerulonephritis (CGN)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Platelets from healthy controls
Number of subjects: 75
Study: 1702148

Group type: EXPERIMENTAL
Intervention: PVB (cisplatin 120 mg/m2 day 3, vinblastine 12 mg/m2 day 1, bleomycin 15 U/m2 twice per week)
Number of subjects: 160

Group type: COMPARATOR
Intervention: VPV (vinblastine 8 mg/m2 day 1, cisplatin 120 mg/m2 day 3, VP‐16 50 mg/m2 days 2 to 5)
Number of subjects: 160

Group type: COMPARATOR
Intervention: VPV
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: PVB
Number of subjects: 160
Study: 6342928

Group type: COMPARATOR
Intervention: 0.8% sodium monofluorophosphate (MFP)
Number of subjects: 1319

Group type: EXPERIMENTAL
Intervention: 3% sodium trimetaphosphate (TMP)
Number of subjects: 1319

Group type: COMPARATOR
Intervention: Control group (0.8% sodium monofluorophosphate)
Number of subjects: 1319
Study: 31301135

Group type: EXPERIMENTAL
Intervention: Vaccine-encoded adapted epitopes
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Higher HLA-I adaptation to the Gag vaccine insert
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: HLA-I adaptation
Number of subjects: 2
Study: 28756744

Group type: EXPERIMENTAL
Intervention: Real stimulation (tDCS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10
Study: 26194728

Group type: EXPERIMENTAL
Intervention: Suvorexant 40 mg (multiple doses)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Suvorexant 40 mg (single dose)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (single dose)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (multiple doses)
Number of subjects: 26
Study: 24452777

Group type: EXPERIMENTAL
Intervention: Self-generated movements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human kinematic profile
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-human kinematics (tempo-matched)
Number of subjects: 0
Study: 23158943

Group type: EXPERIMENTAL
Intervention: CPM combined with Tuina treatment
Number of subjects: 66

Group type: COMPARATOR
Intervention: Continuous passive training (CPM)
Number of subjects: 66
Study: 21048484

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt (one cup, three times per day for 14 days)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 81
Study: 17621221

Group type: EXPERIMENTAL
Intervention: rhBMP-2
Number of subjects: 148

Group type: COMPARATOR
Intervention: ICBG
Number of subjects: 148
Study: 16308382

Group type: EXPERIMENTAL
Intervention: Animal facilitated therapy with dolphins
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 11964641

Group type: EXPERIMENTAL
Intervention: 2 mL lidocaine (Group A, n=60)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1 mL lidocaine combined with 1 mL triamcinolone (Group B, n=60)
Number of subjects: 120
Study: 9817168

Group type: EXPERIMENTAL
Intervention: TGF‐beta1 levels in bronchoalveolar lavage (BAL) fluid from sarcoidosis patients with altered lung function
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: TGF‐beta1 levels in BAL fluid in active sarcoidosis
Number of subjects: 73

Group type: COMPARATOR
Intervention: TGF‐beta1 levels in BAL fluid
Number of subjects: 73

Group type: COMPARATOR
Intervention: TGF‐beta1 levels in AM supernatants
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Correlation of TGF‐beta1 levels in BAL with lymphocyte percentage
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry staining of TGF‐beta1
Number of subjects: 73
Study: 7623251

Group type: EXPERIMENTAL
Intervention: Topical ketorolac rinse (0.1%) with placebo capsule
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Systemic flurbiprofen (50 mg bid) with placebo rinse
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo rinse and capsule
Number of subjects: 55
Study: 2525351

Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg/kg i.v. as a bolus (30 s) before anesthesia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg/kg i.v. as a bolus (30 s) during anesthesia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg/kg i.v. as a bolus (30 s) during extracorporeal circulation (ECC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline solution as placebo (control group) before anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline solution as placebo (control group) during anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline solution as placebo (control group) during ECC
Number of subjects: 60
Study: 14155158

Group type: EXPERIMENTAL
Intervention: Pargyline hydrochloride
Number of subjects: 25
Study: 31013499

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment combined with conventional treatment (treatment group)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional treatment only (control group)
Number of subjects: 59
Study: 27676634

Group type: EXPERIMENTAL
Intervention: 1.25 mg oral D2 agonist bromocriptine
Number of subjects: 18

Group type: COMPARATOR
Intervention: 1.5 mg oral haloperidol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 18
Study: 25652002

Group type: EXPERIMENTAL
Intervention: Tango dancing
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Treadmill training
Number of subjects: 120

Group type: COMPARATOR
Intervention: Stretching (control)
Number of subjects: 120
Study: 24180001

Group type: EXPERIMENTAL
Intervention: Combination ART and maraviroc
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 16441740

Group type: EXPERIMENTAL
Intervention: 2% minocycline gel
Number of subjects: 40

Group type: COMPARATOR
Intervention: Scaling and root planing only (debridement)
Number of subjects: 40
Study: 12900741

Group type: EXPERIMENTAL
Intervention: Tl-201 SPECT in patients with ischemic cardiomyopathy
Number of subjects: 29
Study: 10731775

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8856421

Group type: EXPERIMENTAL
Intervention: Imipramine treatment (4 weeks duration)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo washout
Number of subjects: 40
Study: 1622639

Group type: EXPERIMENTAL
Intervention: FEC monthly (5-fluorouracil 500 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 500 mg/m2)
Number of subjects: 174

Group type: COMPARATOR
Intervention: FEC weekly (5-fluorouracil 500 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 500 mg/m2)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: FEC monthly
Number of subjects: 174

Group type: COMPARATOR
Intervention: FEC weekly
Number of subjects: 174
Study: 6469175

Group type: EXPERIMENTAL
Intervention: Theophylline sodium glycinate
Number of subjects: 6

Group type: COMPARATOR
Intervention: Theophylline ethylenediamine
Number of subjects: 6
Study: 31113214

Group type: EXPERIMENTAL
Intervention: Disability education program including bedside teaching of physical examination/interview skills and case‐based discussion
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Disability education program
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 23
Study: 28527926

Group type: EXPERIMENTAL
Intervention: TEVAR (Bolton Relay Thoracic Stent Graft)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: TEVAR (Relay Plus Delivery System)
Number of subjects: 120
Study: 25881576

Group type: EXPERIMENTAL
Intervention: Higher intensity CRRT (40 mL/kg per hour)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lower intensity CRRT (25 mL/kg per hour)
Number of subjects: 24
Study: 22721550

Group type: EXPERIMENTAL
Intervention: Normal sleep
Number of subjects: 19

Group type: COMPARATOR
Intervention: 27h total sleep deprivation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: PVT performance
Number of subjects: 19
Study: 21185975

Group type: EXPERIMENTAL
Intervention: Choices nutrition logo used in intervention cafeterias (n=13) for a 3-week period.
Number of subjects: 368

Group type: COMPARATOR
Intervention: Control cafeterias (n=12) without the Choices logo.
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Choices nutrition logo intervention.
Number of subjects: 368
Study: 19336732

Group type: EXPERIMENTAL
Intervention: Single-dose cruciferous diet
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Double-dose cruciferous diet
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cruciferous plus apiaceous diet
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: All vegetable-containing diets
Number of subjects: 70
Study: 17785485

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 19979

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 19979
Study: 15566625

Group type: EXPERIMENTAL
Intervention: Fish oil (6 g per day containing 1.5 g DHA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (6 g per day of olive oil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment controls
Number of subjects: 0
Study: 11678781

Group type: EXPERIMENTAL
Intervention: Artesunate 100 mg on days -5, 1, and 5; artemisinin 500 mg on days 1 and 5.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Artemisinin 500 mg on days -5, 1, and 5; artesunate 100 mg on days 1 and 5.
Number of subjects: 20
Study: 9577289

Group type: EXPERIMENTAL
Intervention: Ranitidine 0.5 mg/kg body weight twice a day for preterm infants
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ranitidine 1.5 mg/kg body weight three times a day for term infants
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ranitidine treatment
Number of subjects: 16
Study: 7870540

Group type: EXPERIMENTAL
Intervention: Verbal tests
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Field-independent students
Number of subjects: 109

Group type: COMPARATOR
Intervention: Color coding
Number of subjects: 109
Study: 3276111

Group type: EXPERIMENTAL
Intervention: Calcium heparin, 12,500 IU by the subcutaneous route
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo by the intramuscular route
Number of subjects: 24
Study: 27888254

Group type: EXPERIMENTAL
Intervention: Aerie Real images (not digitally modified)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Digitally modified images from previous campaigns
Number of subjects: 200
Study: 28856854

Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound (HIFU)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Laparoscopic myomectomy (LM)
Number of subjects: 166
Study: 26887879

Group type: EXPERIMENTAL
Intervention: Portable domestic pelvic floor neuromuscular electrical stimulation for 12 weeks after 4 weeks of hospital treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pelvic floor electrophysiological treatment in hospital for 4 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Portable domestic pelvic floor neuromuscular electrical stimulation
Number of subjects: 60
Study: 23473546

Group type: EXPERIMENTAL
Intervention: Asenapine (ASE)
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Olanzapine (OLA)
Number of subjects: 960

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 960
Study: 21499083

Group type: EXPERIMENTAL
Intervention: latanoprost 0.005%
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: travoprost 0.004%
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Number of subjects: 69
Study: 19107187

Group type: EXPERIMENTAL
Intervention: Visual training with six highly similar bird types; specific details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual training with similar birds without established category-boundaries; specific details on dosage and duration not available.
Number of subjects: 0